Anlotinib added to third generation EGFR tyrosine kinase inhibitor therapy for advanced NSCLC patients with oligo-progression: a retrospective study (ALTER-L058)

Anlotinib, when added onto EGFR TKI therapy following gradual progression or oligo-progression, conferred significant PFS benefits upon <i>EGFR</i> mutant NSCLC patients, supporting adding anlotinib to ongoing first-line EGFR TKI therapy for oligoprogressive disease.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2025-11-07
DOI
https://doi.org/10.3389/fphar.2025.1686364
Primary Topic
Lung Cancer Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Anlotinib added to third generation EGFR tyrosine kinase inhibitor therapy for advanced NSCLC patients with oligo-progression: a retrospective study (ALTER-L058)

Fei Zhou, Guilin Zeng, Kangwu Wang, Minglei Zhuo et al.
Frontiers in Pharmacology
Lung Cancer Research Studies
article

Anlotinib added to third generation EGFR tyrosine kinase inhibitor therapy for advanced NSCLC patients with oligo-progression: a retrospective study (ALTER-L058)

Fei Zhou, Guilin Zeng, Kangwu Wang, Minglei Zhuo, Nong Yang, Zhengxiang Han, Dabing Huang, Jun Li, Ling Li, Jian Chen, Hongmin Wang, Jisheng Li, Caicun Zhou, Jin Shi, Fengming Ran, Jinghui Bai, Yang Song
article en

Abstract

Anlotinib, when added onto EGFR TKI therapy following gradual progression or oligo-progression, conferred significant PFS benefits upon <i>EGFR</i> mutant NSCLC patients, supporting adding anlotinib to ongoing first-line EGFR TKI therapy for oligoprogressive disease.

Frontiers in PharmacologyVol. 16
Qingdao University (CN), University of Science and Technology of China (CN), Xuzhou Medical College (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking University (CN), Yuhuangding Hospital (CN), Peking University Cancer Hospital (CN), Second People Hospital of Hunan (CN), Guangzhou First People's Hospital (CN), Shanghai East Hospital (CN), Chengdu Fifth People's Hospital (CN), Tengzhou Central People's Hospital (CN), Xian Yang Central Hospital (CN), First Affiliated Hospital of Bengbu Medical College (CN), First Affiliated Hospital of Zhengzhou University (CN), Tongji Hospital (CN), Hubei Cancer Hospital (CN), Liaoning Cancer Hospital & Institute (CN), Qilu Hospital of Shandong University (CN), Guangzhou Medical University (CN), Air Force Medical University (CN)
Openalex Percentile: Top 55%
Lung Cancer Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.